Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
P/S ratio for Titan Pharmaceuticals, Inc. (TTNP)
P/S ratio as of 2023: 33.72
According to Titan Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 33.72. At the end of 2022 the company had a P/S ratio of 174.64.
P/S ratio history for Titan Pharmaceuticals, Inc. from 1995 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 33.72 |
| 2022 | 174.64 |
| 2021 | 6.50 |
| 2020 | 2.57 |
| 2019 | 0.04 |
| 2018 | 25.40 |
| 2017 | 2622.82 |
| 2016 | 110.12 |
| 2015 | 1065.64 |
| 2014 | 237.79 |
| 2013 | 95.99 |
| 2012 | 204.94 |
| 2011 | 333.99 |
| 2010 | 140.34 |
| 2009 | 34349.81 |
| 2008 | 10058.40 |
| 2007 | 60467.46 |
| 2006 | 79000.41 |
| 2005 | 10534.40 |
| 2004 | 65484.16 |
| 2003 | 18394.21 |
| 2002 | 274.59 |
| 2001 | 1189.52 |
| 2000 | 9672.64 |
| 1999 | 20499.85 |
| 1998 | 10039.72 |
| 1997 | 96.86 |
| 1996 | 6850.14 |
| 1995 | 9689.72 |